RBC Capital Remains a Buy on HCA Healthcare (HCA)

Business Insider

16-07-2025

RBC Capital analyst Ben Hendrix maintained a Buy rating on HCA Healthcare on July 14 and set a price target of $404.00. The company's shares closed yesterday at $371.80.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hendrix covers the Healthcare sector, focusing on stocks such as Cigna, HCA Healthcare, and Humana. According to TipRanks, Hendrix has an average return of 3.2% and a 48.41% success rate on recommended stocks.
HCA Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $395.33, implying a 6.33% upside from current levels. In a report released on July 10, Barclays also maintained a Buy rating on the stock with a $416.00 price target.
The company has a one-year high of $417.14 and a one-year low of $289.98. Currently, HCA Healthcare has an average volume of 1.47M.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year. Most recently, in May 2025, Jon Foster, the EVP & COO of HCA sold 15,698.00 shares for a total of $5,797,585.36.